Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07MCA
|
||||
Former ID |
DNCL003337
|
||||
Drug Name |
FK949E
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Alcohol use disorders [ICD9: 303; ICD10:F10.2] | Phase 3 | [525091] | ||
Company |
Astellas
|
||||
Structure |
Download2D MOL |
||||
Formula |
C25H29N3O6S
|
||||
Canonical SMILES |
C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=CC(=O)O<br />)C(=O)O
|
||||
InChI |
1S/C21H25N3O2S.C4H4O4/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21;5-3(6)1-2-4(7)8/h1-8,25H,9-16H2;1-2H,(H,5,6)(H,7,8)/b;2-1+
|
||||
InChIKey |
VRHJBWUIWQOFLF-WLHGVMLRSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | 5-HT 2 receptor | Target Info | Modulator | [526036], [534577] | |
References | |||||
Ref 526036 | D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001 Apr;11(2):105-10. | ||||
Ref 534577 | Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology(Berl). 1998 Jan;135(2):119-26. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.